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We found that DPAA accumulated in the central nervous 
system tissues for a longer period than in other tissues. This 
finding would extend our knowledge on the distribution 
dynamics and metabolism of DPAA in primates, includ-
ing humans. Furthermore, it may be useful for developing 
a treatment strategy for patients who are exposed to DPAA.
Keywords LC–MS · Macaca fascicularis · Cerebrum · 
Cerebellum · Primate · Phenyl arsenic compound
Introduction
Seaweed contains a large number of organic arsenic com-
pounds, including non-toxic compounds, and many toxic 
compounds are synthesized as pharmaceutical and chemi-
cal warfare agents. Diphenylarsinic acid (DPAA) is an 
organic arsenic compound that was used for the synthesis 
of chemical weapons during World War II (Kurata 1980). 
In 2003, several patients with illnesses of unknown origin 
were reported in Ibaraki Prefecture, Japan. Organic arse-
nic compounds that were found in the wells of Kamisu city 
in Ibaraki were identified as the cause of these symptoms 
(Ishii et  al. 2004). Contaminated water from one of the 
wells contained 4.5 mg As/L of DPAA, which is approxi-
mately 450 times higher than the concentration permitted 
by the drinking water quality standards in Japan (Kinoshita 
et  al. 2005; Shibata et  al. 2005). A total of 157 residents 
who were exposed to DPAA presented with progressive 
cerebellar and brain stem symptoms, including nystagmus, 
dizziness, ataxic gait, tremors, myoclonus and dysarthria, 
along with temporal and occipital lobe symptoms, includ-
ing memory impairment, sleep disturbance, and visual dis-
orders, as well as cerebral atrophy and mental retardation in 
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children. The patients have been receiving regular medical 
checkups for more than 10 years.
Although mounting evidence strongly suggests that 
these neurological symptoms were caused by DPAA (Ishii 
et  al. 2004), our knowledge about the in vivo distribution 
and effects of DPAA remains limited. The effects of DPAA 
in higher vertebrates have been demonstrated using rodents. 
The oral administration of DPAA to mice led to higher 
accumulation of DPAA in the brain than in the liver (Ozone 
et al. 2010). Furthermore, DPAA has been reported to dam-
age the Purkinje cells and cause behavioral impairment in 
mice (Ozone et  al. 2010; Umezu et  al. 2012). In rats, the 
oral administration of DPAA led to a higher accumula-
tion of DPAA in the brain and pancreas in comparison to 
inorganic arsenic compounds (Naranmandura et al. 2009), 
as well as behavioral impairment (Negishi et al. 2013). We 
previously administered DPAA to rats and established a 
rodent model with the same acute cerebellar and brain stem 
symptoms as those of patients in Kamisu (Masuda and 
Ishii, unpublished observation). However, their symptoms 
lasted for a shorter period compared to those of the patients 
(Masuda and Ishii, unpublished observation). Several stud-
ies have also shown that the distribution and metabolism 
of arsenic compounds are different among rodents and 
primates (Vahter and Marafante 1985; Vahter et  al. 1995; 
Aposhian 1997). Therefore, it is difficult for us to predict 
the pattern of DPAA accumulation in the human central 
nervous system (CNS) solely based on the data from rodent 
studies. Thus, we decided to use primates to examine the 
accurate distribution of DPAA in the human CNS. The only 
primate study in relation to DPAA investigated the DPAA 
concentrations in the blood, urine, and feces of primates 
after oral administration (Kobayashi et al. 2008).
Previously, DPAA and its related metabolites have been 
identified in biological and environmental samples using 
liquid chromatography (LC) coupled with induced coupled 
plasma ionization mass spectrometry (ICP–MS), in which 
they were detected as arsenic atom-containing compounds 
(Kobayashi et al. 2008; Hempel et al. 2009). In the present 
study, we adopted isotope dilution LC–mass spectrometry 
(LC–MS). Internal standard compounds of DPAA and their 
metabolites labeled with 13C were added to the tissue sam-
ples. Unlabeled target phenyl arsenic compounds and their 
corresponding isotope-labeled congeners were extracted 
and subjected to LC–MS. Isotope dilution LC–MS is 
extremely useful because it can provide exact compensa-
tion of extraction recovery from biological samples and 
efficient mass spectrometric ionization.
In the present study, we used cynomolgus monkeys 
to predict the distribution and metabolism of DPAA in 
humans. We measured the concentration of DPAA in vari-
ous tissue samples by LC–MS at 5–339 days after the last 
administration of DPAA.
Materials and methods
Arsenic
Phenyl arsenic compounds [DPAA (>99.0%), DPMAO 
(diphenylmethylarsine oxide: >99.0%), phenylmethy-
larsinic acid (PMAA: >99.0%), phenyldimethylarsine 
oxide (PDMAO: >99.0%), and phenylarsonic acid (PAA: 
>99.0%)] were purchased from Tri Chemical Laborato-
ries (Yamanashi, Japan) and stored at 4 °C in the dark. 
Stable radioactive isotopes (13C-DPAA, 13C-DPMAO, 
13C-PMAA, 13C-PDMAO, and 13C-PAA: >95.0%) were 
produced by Hayashi Pure Chemical Industries (Osaka, 
Japan).
Animals
Twenty-eight cynomolgus monkeys (Macaca fascicula-
ris) were purchased from the HAMRI CO., LTD. (Ibaraki, 
Japan). The average weights of the male and female mon-
keys were 3.44  kg (n = 14) and 2.81  kg (n = 14), respec-
tively. The administration of DPAA to the monkeys and tis-
sue sampling were performed at LSI Medience Corporation 
(Tokyo, Japan). All of the experiments were conducted in 
accordance with the Guidelines for Proper Conduct of Ani-
mal Experiments by the Science Council of Japan.
Animal experiments and the sampling of tissues 
and body fluids
DPAA was dissolved in distilled water at a concentration of 
10 mg/mL and the pH was adjusted to 7.0 with 1 N NaOH. 
It was then administrated through a nasogastric tube at a 
dose of 1.0 mg/kg/day. This concentration was determined 
based on the approximate levels of human exposure in 
Kamisu. After the repeated administration of DPAA for 
28 days, the monkeys were divided into four groups. Mon-
keys in the first group (n = 6), second group (n = 6), third 
group (n = 8) and fourth group (n = 8) were euthanized 
at 5, 29, 170, and 339  days after the last administration, 
respectively.
After their euthanization, the following tissue types were 
excised and collected: eight types derived from the CNS, 
the sciatic nerves, three types from the emunctories, eight 
types from the urogenital system, seven types from the 
digestive system, four types from the lymph system, four 
types from the exocrine system, three types from the endo-
crine system, two types from the respiratory system, two 
types from the muscular system, two types from the sense 
organs, and two types from the blood–vascular system (see 
Tables). These samples were then frozen in liquid nitrogen 
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and stored at −80 °C. Also, four types of body fluids (cer-
ebrospinal fluid, bile, hemocyte, and serum) were collected 
and stored at −80 °C.
Extraction of phenyl arsenic compounds
20% of the homogenates of tissue samples were prepared 
in 50 mM ammonium acetate solution (Wako Pure Chemi-
cal Industries, Ltd., Osaka, Japan) using a Teflon homog-
enizer (Ikemoto Scientific Technology Co., Ltd., Tokyo, 
Japan). Then, these homogenized samples, as well as the 
cerebrospinal fluid (CSF) and bile samples were ultra-cen-
trifuged at 105,000×g at 4 °C and the supernatants were 
obtained. The collected blood was centrifuged at 3000×g 
for 10 min and separated into hemocytes and serum. The 
hemocytes were washed three times with 50 mM of Tris-
buffered saline (pH 7.4). Thereafter, 10 mM of Tris–HNO3 
buffer was added to the hemocyte solution and centrifuged 
at 15,000×g for 30 min.
Next, 0.1  mL of bovine serum albumin (80  mg/mL; 
Takara Bio Inc., Shiga, Japan), 1 mL of 4 M NaOH, and 
0.9  mL of  H2O were added to 0.1  g of the samples pre-
pared above. Then, stable radioactive isotopes 13C-DPAA, 
13C-DPMAO, 13C-PMAA, 13C-PDMAO, and 13C-PAA 
(each 100 ppb) were added to the mixed solution and incu-
bated at 90 °C for 3  h. After adding diethyl ether (Wako 
Pure Chemical Industries, Ltd.: >99.5%), the mixed solu-
tion was centrifuged for 5  min to extract phenyl arsenic 
compounds with diethyl ether. The diethyl ether was then 
removed from the phenyl arsenic compounds using a 
stream of dry  N2. After the addition of nitric acid (Wako 
Pure Chemical Industries, Ltd.), the phenyl arsenic com-
pounds were completely dissolved in 10 mL of  H2O.
Analysis of phenyl arsenic
Shiseido Nanospace SI-2 (Shiseido Co., Ltd., Tokyo, 
Japan) and TSQ Quantum Ultra (Thermo Fisher Sci-
entific Corp., CA, USA) LC–MS instruments were 
used. Chromatographic separation was achieved using 
two reversed-phase columns (Imtakt Unison UK-C18; 
150 × 3.0 mm i.d., 3 µm thickness, Kyoto, Japan; Imtakt 
Unison UP-Phenyl, 150 × 3.0  mm i.d., 3  µm thickness) 
at 40 °C. 50 µL of sample solution was injected. In both 
columns, elution was performed using a linear gradient 
of 0.1% formic acid (Wako Pure Chemical Industries, 
Ltd.: 99.0%) in water [A] with 0.1% formic acid in meth-
anol–water (1:9, v/v) [B] as follows: 95% [A]: 5% [B] 
(5-min hold), 95% [A]: 5% [B] to 100% [B] (5–10 min), 
100% [B] (5-min hold), 100% [B] to 95% [A]: 5% 
[B] (20–10  min), 95% [A]: 5% [B] (14-min hold). The 
flow rate was maintained at 0.25  mL/min. Electrospray 
ionization was performed in positive ionization mode. 
The [M + H]+ions of the targeted compounds (DPAA, 
13C-DPAA, DPMAO, 13C-DPMAO, PMAA, 13C-PMAA, 
PDMAO, 13C-PDMAO, PAA, 13C-PAA) were selected 
as the precursor ions. Selected reaction monitoring was 
used to quantify each compound. The precursor and 
product ions were monitored. The collision energies of 
the compounds were as follows: m/z 263 > 152, 30  eV 
for DPAA; m/z 275 > 158, 30  eV for 13C-DPAA; m/z 
261 > 154, 35 eV for DPMAO; m/z 273 > 160, 35 eV for 
13C-DPMAO; m/z 203 > 77, 21 eV for PAA; m/z 209 > 83, 
21 eV for 13C-PAA; m/z 201 > 77, 35 eV for PMAA; m/z 
207 > 83, 35  eV for 13C-PMAA; m/z 199 > 169, 25  eV 
for PDMAO; and m/z 205 > 175, 25 eV for 13C-PDMAO. 
To determine the compounds with greater precision, we 
monitored the other product ions as well: m/z 203 > 185 
for PAA; m/z 201 > 94 for PMAA; m/z 199 > 77 for 
PDMAO. The MS parameters for the analysis were as 
follows: spray voltage, 4000 V; sheath gas  (N2) pressure, 
6 Pa; auxiliary gas  (N2) pressure, 0.5 Pa; capillary tem-
perature, 230 °C; vaporizing temperature, 450 °C; tube 
lens offset, 100  V; collision gas (Ar) pressure, 0.2  Pa. 
Data acquisition and instrument control were performed 
using the Xcalibur software program (Thermo Fisher Sci-
entific Corp.).
Also, a phenyl column was used for the qualitative con-
firmation of the target compounds detected in the C18 
column analysis, and to avoid the false-positive detection 
of the target compounds in the C18 column analysis. The 
retention times, peak widths at half height, and the limit 
of detection (LOD, signal-to-noise ratio = 3) of the phenyl 
arsenic compounds in aqueous solution on the C18 col-
umn analysis were 14.2  min, 0.086  min, and 14  pg/mL, 
respectively, for DPAA; 13.8 min, 0.066 min, and 6.2 pg/
mL for DPMAO; 12.4 min, 0.086 min, and 140 pg/mL for 
PAA; 12.5 min, 0.065 min, and 130 pg/mL for PMAA; and 
11.8 min, 0.097 min, and 62 pg/mL for PDMAO. Similarly, 
the values for the phenyl arsenic compounds that were 
run on the phenyl column were 14.3 min, 0.086 min, and 
25  g/mL, respectively, for DPAA; 14.2  min, 0.063  min, 
and 18  pg/mL for DPMAO; 11.4  min, 0.233  min, and 
910 pg/mL for PAA; 12.4 min, 0.106 min, and 83 pg/mL 
for PMAA; and 12.2 min, 0.064 min, and 130 pg/mL for 
PDMAO. The LOD values for the tissue extract samples 
were higher than those for aqueous solution, depending on 
the tissue sample matrix. This was due to interference from 
the matrix, which typically suppresses the ionization of the 
target compounds and prevents the detection of peaks with 
overlapping matrix components. In the C18 column analy-
sis, the relative intra-day deviations (n = 4) of the peak area 
ratios on the product ion spectra for arsenic compounds 
(20  ng/mL) to those for corresponding 13C-labelled ones 
(5  ng/mL; internal standards) were 0.9, 1.8, 2.7, 5.5, and 
3.5% for DPAA, DPMAO, PAA, PMAA and PDMAO, 
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respectively. The relative intra-day deviations in the phenyl 
column analysis (n = 5) were 3.6, 1.3, 7.9, 4.2, and 3.7%, 
respectively.
Data analysis
To calculate the half-life (T1/2; the time required for the 
concentration to decrease to half its initial value) of DPAA, 
we plotted the DPAA concentrations (at 5 and 29 days after 
the last administration of DPAA) in each of tissue and body 
fluid sample against the concentration values on the loga-
rithmic scale. The half-lives were calculated based on the 
slope of the decay lines (slope = −k/2.303, T1/2 = 0.693/k).
Statistical analyses and preparation of approximate 
graph curves
Tukey’s method was used for multiple group comparisons. 
The JMP software program (version 5.12-J, SAS Institute 
Inc., NC, USA) was used to perform the statistical analyses. 
P values of <0.05 were considered to indicate statistical 
significance. The JMP software program (version 5.12-J) 
was also used to perform a curvilinear regression analysis, 
which allowed us to approximate the quadratic curves.
Results
Liquid chromatography–mass spectrometry
DPAA and its related metabolites were identified in tis-
sue samples by LC–MS using the isotope dilution method. 
These phenyl arsenic compounds were well separated in 
LC conditions using both C18 and phenyl columns. The 
[M + H]+ ions of the target compounds were carefully 
observed by electrospray ionization. 50  µL of the sample 
solution was injected into the LC–MS system to achieve 
optimal detection sensitivity. Imtakt Unison columns ena-
bled large-volume injection without compromising the peak 
resolution. During selected reaction monitoring (SRM), the 
product ions and collision energies were selected by opti-
mizing the conditions in the product ion scan spectra of 
the target precursor ions. A typical SRM chromatogram for 
the control phenyl arsenic compounds is shown in Fig. 1. 
Calibration curves were prepared for the peak area ratios 
of the target phenyl arsenic compounds of the correspond-
ing 13C-labeled internal standards on the respective SRM 
chromatograms. We first used a C18 column to determine 
the target compounds in the samples. If positive peaks were 
observed on SRM, the presence of the corresponding prod-
uct ion peaks was tested for PAA, PMAA, and PDMAO to 
Fig. 1  A selected reaction 
monitoring chromatogram for 
the phenyl arsenic compounds 
in aqueous solution. 50 µL of 
DPAA, DPMAO, PAA, PMAA, 
and PDMAO solution (each 
33.3 ng/mL) was injected into 
the LC–MS system fitted with 
a C18 column. The 100% ionic 
intensities and mass transitions 
are shown on the right. (Color 
figure online)
DPAA
DPMAO
PAA
PMAA
PDMAO
m/z 199>77
m/z 199>169
m/z 201>77
m/z 201>94
m/z 203>77
m/z 203>185
m/z 261>154
m/z 263>152
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Table 1  DPAA concentration in the tissues of cynomolgus monkeys after oral administration of DPAA
DPAA (ng As/g) after administration Half-life 
of DPAA 
(day)Days 5 (average ± SEM) Days 29 (aver-age ± SEM)
Days 170 (aver-
age ± SEM)
Days 339 (aver-
age ± SEM)
Central nervous system
 Cervical spinal cord 588 ± 58.9 (6) 183 ± 12.6 (6) 47.0 ± 3.20 (8) 29.4 ± 3.85 (8) 14.4
 Thoracic spinal cord 527 ± 39.1 (6) 167 ± 13.5 (6) 48.5 ± 3.69 (8) 27.4 ± 2.22 (8) 14.4
 Lumbar spinal cord 633 ± 84.5 (6) 187 ± 18.0 (6) 40.0 ± 4.32 (8) 20.3 ± 2.70 (8) 13.9
 Upper brain stem 659 ± 66.4 (4) 222 ± 10.7 (3) 51.8 ± 3.45 (8) 30.2 ± 4.93 (4) 15.4
 Intermediate brain stem 686 ± 77.9 (4) 243 ± 8.05 (4) 55.7 ± 4.33 (8) 36.0 ± 8.10 (4) 16.1
 Lower brain stem 682 ± 83.6 (4) 216 ± 15.7 (4) 47.4 ± 2.67 (8) 23.0 ± 3.79 (4) 14.7
 Upper cerebellum 446 ± 38.0 (4) 115 ± 10.4 (4) 13.3 ± 1.81 (8) 5.90 ± 2.25 (4) 12.4
 Lower cerebellum 470 ± 74.0 (4) 124 ± 9.05 (4) 13.2 ± 1.85 (8) 7.53 ± 1.68 (4) 12.6
 Frontal lobe 517 ± 48.3 (4) 145 ± 12.7 (4) 12.5 ± 1.44 (8) 6.45 ± 1.82 (4) 13.1
 Parietal lobe 681 ± 89.0 (4) 199 ± 9.63 (4) 25.9 ± 4.42 (8) 13.6 ± 2.57 (4) 13.9
 Temporal lobe 518 ± 49.8 (4) 173 ± 23.6 (4) 13.0 ± 2.12 (8) 6.53 ± 2.47 (4) 15.1
 Occipital lobe 830 ± 116 (4) 227 ± 36.3 (4) 37.5 ± 5.34 (8) 20.9 ± 1.60 (4) 12.8
 Hippocampus 531 ± 51.9 (4) 128 ± 13.0 (4) 16.6 ± 5.05 (8) 5.12 ± 2.18 (4) 11.7
 Striatum 772 ± 116 (4) 254 ± 28.0 (4) 35.9 ± 4.09 (8) 25.2 ± 5.45 (4) 15.1
 Cingulate gyrus 493 ± 42.1 (4) 143 ± 23.8 (4) 12.7 ± 2.76 (8) 3.19 ± 0.571 (4) 13.1
Central nervous system 
(total)
600 ± 21.2 (66)* 181 ± 6.60 (65)* 31.4 ± 1.71 (120)* 18.8 ± 1.48 (72)* 14.4*
Peripheral nervous system
 Sciatic nerve 480 ± 50.0 (6)* 250 ± 23.9 (6)* 2.94 ± 0.427 (8) 0.841 ± 0.174 (8) 25.7*
Emunctories
 Liver 555 ± 106 (6) 16.8 ± 3.09 (6) 0.263 ± 0.0543 (8) 0.0620 ± 0.0327 (8) 4.72
 Gall bladder 1041 ± 224 (4) 36.5 ± 9.51 (4) 0.732 ± 0.0969 (8) 0.148 ± 0.0569 (8) 4.92
 Kidney 532 ± 60.9 (6) 34.5 ± 4.72 (6) 0.378 ± 0.0381 (8) 0.0341 ± 0.0130 (8) 6.03
Emunctories (total) 1033 ± 188 (20)* 41.6 ± 8.32 (20)* 0.761 ± 0.117 (32) 0.148 ± 0.0302 (31) 5.13
Urogenital system
 Bladder 46.5 ± 11.0 (6) 4.48 ± 0.615 (6) 0.213 ± 0.0368 (8) 0 (8) 7.30
 Testicle 21.2 ± 3.83 (3) 1.62 ± 0.140 (3) 0 (4) 0 (4) 6.54
 Seminal vesicle 49.3 ± 6.25 (3) 7.19 ± 1.25 (3) 0.0197 ± 0.0187 (4) 0 (4) 8.56
 Epididymis 38.2 ± 5.32 (3) 4.54 ± 1.02 (3) 0.0727 ± 0.0416 (4) 0.0328 ± 0.0318 (4) 7.70
 Prostate 44.2 ± 8.30 (3) 6.46 ± 1.29 (3) 0.0469 ± 0.0271 (4) 0 (4) 8.66
 Ovary 39.1 ± 10.9 (3) 4.62 ± 1.67 (3) 0.182 ± 0.0679 (4) 0 (4) 7.30
 Uterus 28.3 ± 3.84 (3) 3.83 ± 2.03 (3) 0 (4) 0 (4) 7.30
 Vagina 37.5 ± 3.95 (3) 4.21 ± 1.21 (3) 0.0755 ± 0.0354 (4) 0 (4) 7.30
Digestive system
 Esophagus 29.5 ± 3.98 (6) 2.74 ± 0.411 (6) 0.0905 ± 0.0191 (8) 0.0140 ± 0.0130 (8) 6.93
 Stomach 20.6 ± 2.08 (6) 1.93 ± 0.215 (6) 0.0422 ± 0.0169 (8) 0 (8) 7.00
 Duodenum 55.5 ± 15.0 (6) 6.68 ± 1.43 (6) 0.0751 ± 0.0176 (8) 0 (8) 7.70
 Small intestine 73.0 ± 13.7 (5) 4.05 ± 0.723 (6) 0.0939 ± 0.0186 (8) 0.0377 ± 0.0367 (8) 5.68
 Colon 44.5 ± 9.41 (6) 3.61 ± 0.630 (6) 0.109 ± 0.0202 (8) 0 (7) 6.67
 Rectal 38.5 ± 9.92 (4) 3.01 ± 0.495 (4) 0.123 ± 0.0213 (8) 0 (6) 6.67
 Pancreas 54.6 ± 9.42 (6) 3.14 ± 0.494 (6) 0.0381 ± 0.0186 (8) 0.0147 ± 0.0137 (8) 5.83
Lymph system
 Thymus 54.7 ± 7.15 (6) 3.52 ± 0.772 (6) 0.0917 ± 0.0356 (8) 0 (8) 5.87
 Spleen 44.7 ± 4.58 (6) 2.28 ± 0.283 (6) 0.00839 ± 0.00739 (8) 0 (8) 5.55
 Submandibular node 40.8 ± 3.89 (6) 3.55 ± 0.401 (6) 0.103 ± 0.0183 (7) 0.0166 ± 0.0156 (6) 6.80
 Mesenteric node 49.9 ± 7.18 (4) 3.60 ± 0.686 (4) 0.0845 ± 0.0164 (7) 0 (8) 6.30
Exocrine system
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provide definitive confirmation of their presence, because 
these highly hydrophilic compounds typically suffer from 
severe interference from the biological matrix components 
in sample extracts during LC separation and MS detection.
Quantitative analysis of DPAA in the tissues 
of cynomolgus monkeys
Twenty-eight cynomolgus monkeys were exposed to DPAA 
for 28  days at a dose of 1.0  mg DPAA/kg/day. After the 
oral administration of DPAA, the monkeys were divided 
into four groups (each group contained 6–8 monkeys), 
which were euthanized at 5, 29, 170, and 339 days after the 
last administration of DPAA. The whole tissues and body 
fluids were collected after euthanasia (Table 1).
We measured the concentration of DPAA in the tis-
sues of animals from each group using a LC–MS analysis. 
The concentrations of DPAA in all of the tissues showed 
a gradual decrease with time after the last administra-
tion (Table 2; Fig. 1). At 5 days after the last administra-
tion, we found that the average concentrations of DPAA 
in the tissues derived from the CNS (600 ± 21.2 ng As/g), 
the emunctories (1033 ± 188  ng  As/g), and the sciatic 
nerve (480 ± 50.0  ng  As/g) were significantly higher 
than those derived from other tissues (total 34 tissues, 
43.2 ± 2.49 ng As/g) (Fig. 2; Table 1; p < 0.0001).
At 29  days after the last administration, the aver-
age concentrations of DPAA in the CNS tis-
sues (181 ± 6.60  ng  As/g) and the sciatic nerve 
(250 ± 23.9  ng  As/g) were 30.1 and 52.1% of values at 
the 5-day time point, respectively (Fig.  3; Table  1). On 
the other hand, the average concentrations of DPAA in 
the emunctories (41.6 ± 8.32  ng  As/g) and other tissues 
(4.76 ± 0.311 ng As/g) were drastically lower in compari-
son to those of the group that was euthanized at 5 days after 
the last administration (Fig.  3; Table  1) (4.03 and 11.0% 
The number between brackets indicates the number of samples examined
*p < 0.0001, compared with other tissues
Table 1  (continued)
DPAA (ng As/g) after administration Half-life 
of DPAA 
(day)Days 5 (average ± SEM) Days 29 (aver-age ± SEM)
Days 170 (aver-
age ± SEM)
Days 339 (aver-
age ± SEM)
 Parotid gland 41.3 ± 10.6 (6) 2.20 ± 0.156 (6) 0.0511 ± 0.0170 (8) 0 (8) 6.03
 Submandibular gland 146 ± 35.2 (6) 13.2 ± 1.94 (6) 0.0396 ± 0.0150 (8) 0 (8) 7.53
 Sublingual gland 39.7 ± 9.63 (6) 7.36 ± 1.41 (6) 0.0760 ± 0.0295 (8) 0.0445 ± 0.0215 (8) 9.90
 Lacrimal gland 62.1 ± 11.0 (4) 3.35 ± 0.697 (4) 0.101 ± 0.0237 (6) 0.0175 ± 0.0165 (8) 5.68
Endocrine system
 Adrenal gland 37.4 ± 6.65 (6) 4.07 ± 2.49 (6) 0.0542 ± 0.0322 (8) 0 (8) 6.03
 Pituitary 28.7 ± 2.82 (6) 3.72 ± 0.424 (6) 0.200 ± 0.0382 (8) 0 (8) 8.06
 Thyroid 16.2 ± 3.23 (6) 0.946 ± 0.112 (6) 0 (8) 0.0287 ± 0.0277 (8) 6.03
Respiratory system
 Trachea 20.3 ± 1.46 (6) 4.51 ± 0.750 (6) 1.44 ± 0.168 (8) 0.815 ± 0.119 (8) 10.7
 Lung 106 ± 15.6 (6) 10.4 ± 1.36 (6) 0.227 ± 0.0578 (8) 0.0259 ± 0.0163 (8) 7.15
Muscular system
 Femoral muscle 25.9 ± 3.72 (6) 5.94 ± 0.746 (6) 0.109 ± 0.0247 (8) 0 (8) 11.4
 Tongue 43.0 ± 6.18 (6) 5.31 ± 0.917 (6) 0.0878 ± 0.0245 (8) 0.0213 ± 0.0203 (8) 7.88
Sense organs
 Eyeball 7.80 ± 2.02 (6) 3.06 ± 0.938 (6) 0.260 ± 0.0529 (8) 0.149 ± 0.0492 (8) 20.4
 Skin with hair 49.9 ± 4.02 (6) 16.2 ± 4.27 (6) 1.70 ± 0.410 (8) 0.369 ± 0.255 (8) 12.6
Blood–vascular system
 Heart 48.3 ± 6.20 (6) 6.36 ± 0.740 (6) 0.147 ± 0.0245 (8) 0.00730 ± 0.00630 (8) 8.25
 Aorta 41.9 ± 7.96 (4) 5.12 ± 0.765 (4) 1.17 ± 0.262 (8) 0.458 ± 0.0896 (8) 7.97
Other tissues (total) 43.2 ± 2.49 (188) 4.76 ± 0.311 (187) 0.218 ± 0.0298 (255) 0.0643 ± 0.0139 (255) 7.30
Body fluids
 Cerebrospinal fluid 1.78 ± 0.252 (6) 0.233 ± 0.0268 (6) 0 (8) 0 (6) 8.25
 Bile 2496 ± 287 (4) 94.5 ± 27.4 (4) 1.67 ± 0.228 (8) 0.377 ± 0.0462 (7) 4.88
 Hemocyte 9.03 ± 0.936 (2) 2.05 ± 0.782 (2) 0 (1) – 10.7
 Serum 11.4 ± 2.41 (6) 0.364 ± 0.0458 (6) 0 (8) 0 (8) 4.92
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Table 2  PAA concentration in cynomolgus monkeys after oral administration of DPAA
PAA (ng As/g) after administration
Days 5 (average ± SEM) Days 29 (average ± SEM) Days 170 (average ± SEM) Days 339 (average ± SEM)
Central nervous system
 Cervical spinal cord 1.92 ± 0.439 (6) 1.14 ± 0.254 (6) 0.196 ± 0.0764 (8) 0.0977 ± 0.0771 (8)
 Thoracic spinal cord 1.29 ± 0.442 (6) 0.832 ± 0.269 (6) 0.0668 ± 0.0442 (8) 0.0659 ± 0.0313 (8)
 Lumbar spinal cord 2.15 ± 0.496 (6) 0.965 ± 0.261 (6) 0.273 ± 0.0887 (8) 0.0321 ± 0.0208 (8)
 Brain stem 2.93 ± 1.47 (3) 1.38 ± 1.05 (3) 0.580 ± 0.214 (4) 0.326 ± 0.00590 (2)
 Cerebellum 2.60 ± 1.30 (3) 1.42 ± 0.679 (4) 0.333 ± 0.103 (6) 0 (2)
 Frontal lobe 3.13 ± 1.66 (3) 1.61 ± 0.784 (4) 0.358 ± 0.121 (6) 0.302 ± 0.103 (2)
 Parietal lobe 3.95 ± 2.16 (3) 1.85 ± 0.796 (4) 0.818 ± 0.239 (6) 0.140 ± 0.0311 (2)
 Temporal lobe 2.69 ± 1.71 (3) 1.28 ± 0.794 (4) 0.520 ± 0.188 (6) 0.333 ± 0.332 (2)
 Occipital lobe 7.19 ± 5.10 (3) 2.79 ± 0.497 (4) 0.647 ± 0.0913 (6) 0.123 ± 0.122 (2)
Central nervous system (total) 2.77 ± 0.522 (36) 1.40 ± 0.185 (41) 0.391 ± 0.0500 (58) 0.112 ± 0.0288 (36)
Peripheral nervous system
 Sciatic nerve 0.976 ± 0.392 (6) 0.423 ± 0.194 (6) 0 (8) 0 (8)
Emunctories
 Liver 18.0 ± 7.95 (6) 1.84 ± 0.770 (6) 0.0135 ± 0.0126 (8) 0.0157 ± 0.0147 (8)
 Gall bladder 20.2 ± 11.7 (4) 1.13 ± 0.653 (4) 0.0200 ± 0.0193 (8) 0 (8)
 Kidney 2.69 ± 0.955 (6) 0.482 ± 0.191 (6) 0.0172 ± 0.0163 (8) 0 (8)
Emunctories (total) 12.8 ± 4.36 (16) 1.15 ± 0.351 (16) 0.0170 ± 0.00900 (24) 0.00592 ± 0.00492 (24)
Urogenital system
 Bladder 0.492 ± 0.173 (6) 0.122 ± 0.0570 (6) 0 (8) 0 (8)
 Testicle 0.158 ± 0.0908 (4) 0 (5) 0 (4) 0 (4)
 Seminal vesicle 0.194 ± 0.193 (4) 0 (5) 0 (4) 0 (4)
 Epididymis 0.141 ± 0.140 (4) 0 (5) 0 (4) 0 (4)
 Prostate 0.164 ± 0.163 (4) 0 (5) 0 (4) 0 (4)
 Ovary 0.235 ± 0.146 (5) 0.100 ± 0.0992 (6) 0.0245 ± 0.0235 (8) 0 (4)
 Uterus 0.178 ± 0.119 (5) 0.0253 ± 0.0243 (6) 0 (8) 0 (4)
 Vagina 0.165 ± 0.108 (5) 0.0367 ± 0.0357 (6) 0 (8) 0 (4)
Digestive system
 Esophagus 0.355 ± 0.160 (6) 0.0568 ± 0.0559 (6) 0 (8) 0 (8)
 Stomach 0.208 ± 0.0954 (6) 0.0311 ± 0.0301 (6) 0 (8) 0 (8)
 Duodenum 1.12 ± 0.593 (6) 0.344 ± 0.343 (6) 0 (8) 0 (8)
 Small intestine 1.53 ± 1.13 (5) 0.244 ± 0.243 (6) 0 (8) 0 (8)
 Colon 0.438 ± 0.214 (6) 0.0424 ± 0.0415 (6) 0 (8) 0 (8)
 Rectal 0.144 ± 0.143 (4) 0 (5) 0 (8) 0 (8)
 Pancreas 0.384 ± 0.201 (6) 0.0255 ± 0.0246 (6) 0 (8) 0 (8)
Lymph system
 Thymus 0.868 ± 0.398 (6) 0.0752 ± 0.0743 (6) 0 (8) 0 (8)
 Spleen 0.655 ± 0.295 (6) 0 (6) 0 (8) 0 (8)
 Submandibular node 0.393 ± 0.205 (6) 0 (6) 0 (8) 0.0103 ± 0.00935 (8)
 Mesenteric node 0.123 ± 0.122 (4) 0 (6) 0 (8) 0.0153 ± 0.0144(8)
Exocrine system
 Parotid gland 0.327 ± 0.186 (6) 0 (6) 0 (8) 0 (8)
 Submandibular gland 0.522 ± 0.297 (6) 0 (6) 0 (8) 0 (8)
 Sublingual gland 0.276 ± 0.161 (6) 0 (6) 0 (8) 0 (8)
 Lacrimal gland 0.149 ± 0.148 (4) 0 (6) 0 (8) 0 (8)
Endocrine system
 Adrenal glands 0.415 ± 0.188 (6) 0 (6) 0 (8) 0 (8)
 Pituitary 0.0469 ± 0.0459 (6) 0 (6) 0 (8) 0 (8)
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of values at the 5-day time point, respectively). We also 
examined the half-life of DPAA in each tissue (Table  1). 
The average half-lives of DPAA in the CNS tissues and the 
sciatic nerve (14.4 and 25.7  days, respectively) were sig-
nificantly longer in comparison to DPAA in other tissues 
(p < 0.0001).
In the group that was euthanized at 339  days after the 
last administration, the concentrations of DPAA in all of 
the tissues were more than 96% lower than those in the 
group euthanized at 5  days after the last administration 
(Table 1). Notably, the average concentration of DPAA in 
the CNS tissues (18.8 ± 1.48  ng  As/g) was significantly 
higher than that in all of the other tissues, even at 339 days 
after the last administration (Fig. 3; Table 1; p < 0.0001).
Quantitative analysis of DPAA in the body fluids 
of cynomolgus monkeys
Next, we measured the concentration of DPAA in the 
body fluids of each group using an LC–MS analysis. A 
small amount of DPAA was detected in the serum and 
the hemocytes at 5 and 29  days after the last administra-
tion (Fig. 4; Table 1). It was not detected after these time 
points. Similarly, DPAA was detected at a concentration 
of 0.233 ± 0.0268 ng As/g in the CSF at 29 days, and was 
not detected later (Fig. 4; Table 1). On the contrary, a large 
amount of DPAA was detected in the bile at 5 days after the 
last administration (2496 ± 287 ng As/g) (Table 1); the con-
centration at 29 days after the last administration was 3.79% 
of the value at the 5-day time point (94.5 ± 27.4 ng As/g). 
The average half-life of DPAA in the bile was 4.88 days.
Quantitative analysis of PAA and PMAA in cynomolgus 
monkeys
PAA and PMAA are known to be the major metabo-
lites of DPAA. We measured the concentrations of PAA 
and PMAA in the same tissues of each group described 
above using an LC–MS analysis. We detected very small 
amounts of PAA and PMAA in these tissues at 5–339 days 
after the last administration (Tables  2, 3). The concentra-
tions of PAA and PMAA in the CNS tissues (2.77 ± 0.522 
and 0.973 ± 0.184  ng  As/g, respectively) and emunctories 
(12.8 ± 4.36 and 1.66 ± 0.658 ng As/g, respectively) were a 
little higher than those in other tissues at 5 days after the 
last administration (Tables 2, 3).
Discussion
In the present study, we examined the clearance of orally 
administrated DPAA in cynomolgus monkeys. Our results 
The number between brackets indicates the number of samples examined
Table 2  (continued)
PAA (ng As/g) after administration
Days 5 (average ± SEM) Days 29 (average ± SEM) Days 170 (average ± SEM) Days 339 (average ± SEM)
 Thyroid 0.187 ± 0.0658 (6) 0 (6) 0 (8) 0 (8)
Respiratory system
 Trachea 0.141 ± 0.0465 (6) 0 (6) 0 (8) 0 (8)
 Lung 1.67 ± 0.552 (6) 0 (6) 0 (8) 0 (8)
Muscular system
 Femoral muscle 0.601 ± 0.193 (6) 0 (6) 0 (8) 0 (8)
 Tongue 0.719 ± 0.219 (6) 0 (6) 0 (8) 0.0291 ± 0.0282 (8)
Sense organs
 Eyeball 0.0121 ± 0.0111 (6) 0 (6) 0 (8) 0 (8)
 Skin 0.0854 ± 0.0844 (6) 0 (6) 0 (8) 0 (8)
Blood–vascular system
 Heart 0.0330 ± 0.0317 (6) 0 (6) 0 (8) 0.0320 ± 0.0308 (8)
 Aorta 0.0483 ± 0.0473 (6) 0 (6) 0 (8) 0 (8)
Other tissues (total) 0.402 ± 0.0537 (186) 0.0339 ± 0.0135 (199) 0.00173 ± 0.000735 (256) 0.00371 ± 0.00147 (244)
Body fluids
 Cerebrospinal fluid 0 (6) 0 (6) 0 (8) 0 (8)
 Bile 0 (6) 0 (6) 0 (8) 0 (8)
 Hemocyte 0 (6) 0 (6) 0 (8) 0 (4)
 Serum 0 (6) 0 (6) 0 (8) 0 (8)
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clearly demonstrated that the half-life of DPAA in the brain 
was twice as long as that in other tissues except the emu-
nctories, suggesting that DPAA easily accumulates in the 
brains of cynomolgus monkeys. Together with our pre-
liminary observation that the half-life of DPAA in the rat 
brain after the administration of DPAA (at the same dose 
as this study) was shorter than that of cynomolgus mon-
keys (<8.6  days; Masuda and Ishii, unpublished observa-
tion), the findings suggest that DPAA may accumulate in 
the brains of primates more easily than in the rodent brain. 
Previous experiments using rodents have shown that inor-
ganic arsenic (iAs) can cross the blood–brain barrier (BBB; 
Rodríguez et al. 2005; Juárez-Reyes et al. 2009). Similarly 
to organic arsenic, DPAA was also detected in the CSF 
obtained from the residents of Kamisu who were exposed to 
DPAA (Ishii et al. 2014). Their CSF/serum ratios of DPAA 
were 3.7 and 3.0% at the first and 14th days after their last 
exposure, respectively (Ishii et  al. 2014). Consistent with 
Fig. 2  Approximate curves 
showing the correlation 
between the days after the last 
administration of DPAA and 
the average concentrations of 
DPAA (ng As/g) in tissues of 
cynomolgus monkeys after the 
daily administration of DPAA 
(1.0 mg/kg/day) for 28 days. 
(Color figure online)
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these previous results, DPAA was detected in the CSF of 
cynomolgus monkeys in this study. The average CSF/serum 
ratio of DPAA in this study was 15.7% (5  days after the 
last administration, n = 6). Thus, these results strongly sug-
gest that DPAA may pass through the BBB of primates. 
This may be due to the hydrophobicity of DPAA (Weksler 
et al. 2005; Naranmandura et al. 2009). Also, the reduction 
in blood flow and the cerebral metabolism was observed 
in the brains of the Kamisu residents who were exposed to 
DPAA (unpublished data). This evidence strongly suggests 
that the long presence of DPAA in the human brain may 
affect the brain function.
Several previous studies have shown that small amounts 
of iAs, monomethylarsenous acid (MMA) and dimethyl-
arsinic acid (DMA) accumulated in the rat brain after the 
administration of iAs (Rodríguez et al. 2005, 2010; Juárez-
Reyes et al. 2009). In humans, keratinization and pigmen-
tation of the skin, peripheral neuropathy, skin cancer, and 
peripheral circulatory failure have all been reported as 
symptoms of chronic poisoning from exposure to inorganic 
arsenic compounds; however, there have been few reports 
on CNS symptoms (World Health Organization 2001). Pre-
vious rodent studies have revealed that DPAA, an organic 
arsenic compound, accumulated in the rodent brain more 
easily than inorganic arsenic compounds (Naranmandura 
et  al. 2009; Ozone et  al. 2010). Our study also demon-
strated that DPAA accumulated in the CNS tissues of pri-
mates for a long period after its oral administration. These 
facts are consistent with our previous observations that the 
effects of DPAA on humans were substantially restricted to 
regions of the CNS such as the cerebellum and brain stem 
(Ishii et al. 2004). Furthermore, the cerebellar dysfunction 
found in the recent animal behavior experiments was quite 
similar to that observed in the Kamisu residents who were 
exposed to DPAA (Ozone et al. 2010; Negishi et al. 2013). 
Thus, it is highly likely that the effects of DPAA exposure 
on the CNS of Kamisu residents were caused by its long-
term accumulation in the CNS.
It is known that when DPAA is administered to rats, it is 
excreted in the urine, feces, and hair (Naranmandura et al. 
2009; Kobayashi and Hirano 2013). Although a high level 
of DPAA accumulation was seen in the liver, gallblad-
der, and bile of cynomolgus monkeys at 5  days after the 
last DPAA administration, the half-lives of the DPAA in 
these tissues were as short as those in other tissues. Thus, 
as is the case with rats, DPAA is likely to be excreted in 
the liver, gallbladder, and bile of cynomolgus monkeys. 
While the concentration of DPAA in rat hair at 14  days 
after the last DPAA administration (at the same dose as this 
study) was high (Masuda and Ishii, unpublished observa-
tion), moderate levels of DPAA and its metabolites were 
also detected in the skin with hair of cynomolgus monkeys 
at 5 days after the last DPAA administration in the present 
study. Thus, like the rat, it is highly likely that DPAA and 
its metabolites may be excreted in skin with hair in cyn-
omolgus monkeys.
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Fig. 3  Approximate curves showing the correlation between the days 
after the last administration of DPAA and the average concentrations 
of DPAA (ng As/g) in tissue samples from the CNS, the emunctories, 
the sciatic nerve, and other tissues of cynomolgus monkeys after the 
daily administration of DPAA (1.0 mg/kg/day) for 28 days. The aver-
age values ± SEM for each group are shown using horizontal lines. 
Purple, sciatic nerve; magenta, central nervous system; green, emu-
nctories; blue, other tissues. *p < 0.0001, in comparison to the other 
tissues (the colors of the asterisks correspond to the group)
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Fig. 4  Approximate curves showing the correlation between the days 
after the last administration of DPAA and the average concentra-
tions of DPAA (ng As/g) in the body fluids (cerebrospinal fluid, bile, 
hemocyte and serum) of cynomolgus monkeys after the daily admin-
istration of DPAA (1.0  mg/kg/day) for 28  days. Blue, bile; green, 
hemocyte; yellow, serum; magenta, cerebrospinal fluid
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Table 3  PMAA concentration in cynomolgus monkeys after oral administration of DPAA
PMAA (ng As/g) after administration
Days 5 (average ± SEM) Days 29 (average ± SEM) Days 170 (average ± SEM) Days 339 (average ± SEM)
Central nervous system
 Cervical spinal cord 0.592 ± 0.204 (6) 0.380 ± 0.177 (6) 0.229 ± 0.113 (8) 0.0304 ± 0.0294 (8)
 Thoracic spinal cord 0.511 ± 0.254 (6) 0.416 ± 0.183 (6) 0.226 ± 0.0981 (8) 0.0272 ± 0.0262 (8)
 Lumbar spinal cord 0.599 ± 0.284 (6) 0.387 ± 0.156 (6) 0.196 ± 0.100 (8) 0.0465 ± 0.0455 (8)
 Brain stem 1.86 ± 0.460 (2) 1.61 ± 0.370 (3) 0.146 ± 0.145 (4) 0 (8)
 Cerebellum 2.16 ± 1.29 (2) 0.741 ± 0.377 (4) 0.199 ± 0.0755 (6) 0.166 ± 0.165 (2)
 Frontal lobe 1.54 ± 0.896 (2) 0.523 ± 0.312 (4) 0.0524 ± 0.0514 (6) 0 (8)
 Parietal lobe 2.62 ± 1.20 (2) 0.515 ± 0.312 (4) 0.0690 ± 0.0689 (6) 0 (8)
 Temporal lobe 0.497 ± 0.496 (2) 0.143 ± 0.142 (4) 0 (8) 0 (8)
 Occipital lobe 0.813 ± 0.812 (2) 0.454 ± 0.264 (4) 0.0601 ± 0.0591 (6) 0 (8)
Central nervous system (total) 0.973 ± 0.184 (30) 0.523 ± 0.0899 (41) 0.139 ± 0.0299 (58) 0.0326 ± 0.0156 (36)
Peripheral nervous system
 Sciatic nerve 0.0391 ± 0.0381 (6) 0.124 ± 0.123 (4) 0 (8) 0 (8)
Emunctories
 Liver 3.77 ± 1.55 (6) 1.60 ± 0.430 (6) 0.0666 ± 0.0372 (8) 0.0762 ± 0.0437 (8)
 Gall bladder 0.543 ± 0.329 (5) 0.112 ± 0.0639 (4) 0.0280 ± 0.0270 (8) 0.0225 ± 0.0215 (8)
 Kidney 0.476 ± 0.244 (6) 0.285 ± 0.106 (6) 0.0608 ± 0.0598 (8) 0.0124 ± 0.0114 (8)
Emunctories (total) 1.66 ± 0.658 (17) 0.736 ± 0.235 (16) 0.0518 ± 0.0243 (24) 0.0371 ± 0.0170 (24)
Urogenital system
 Bladder 0.181 ± 0.0911 (6) 0.0820 ± 0.0810 (4) 0 (8) 0 (8)
 Testicle 0.228 ± 0.160 (5) 0 (8) 0 (8) 0 (8)
 Seminal vesicle 0.145 ± 0.0953 (5) 0 (8) 0 (8) 0 (8)
 Epididymis 0.0997 ± 0.0634 (5) 0 (8) 0 (8) 0 (8)
 Prostate 0.180 ± 0.127 (5) 0 (8) 0 (8) 0 (8)
 Ovary 0.0753 ± 0.0743 (4) 0.0683 ± 0.0673 (4) 0 (8) 0 (8)
 Uterus 0.0722 ± 0.0712 (4) 0.0743 ± 0.0733 (4) 0 (8) 0 (8)
 Vagina 0.0264 ± 0.0254 (4) 0.0912 ± 0.0902 (4) 0 (8) 0 (8)
Digestive system
 Esophagus 0.178 ± 0.0935 (6) 0.0799 ± 0.0789 (4) 0 (8) 0 (8)
 Stomach 0.168 ± 0.0837 (6) 0.0536 ± 0.0526 (4) 0 (8) 0 (8)
 Duodenum 0.218 ± 0.107 (6) 0.152 ± 0.0683 (6) 0 (8) 0 (8)
 Small intestine 0.211 ± 0.110 (6) 0.102 ± 0.0544 (6) 0 (8) 0 (8)
 Colon 0.130 ± 0.0625 (6) 0.801 ± 0.711 (6) 0 (8) 0 (8)
 Rectal 0.0699 ± 0.0689 (5) 0 (8) 0 (8) 0 (8)
 Pancreas 0.278 ± 0.175 (6) 0.149 ± 0.107 (4) 0 (8) 0 (8)
Lymph system
 Thymus 0.211 ± 0.140 (6) 0.0821 ± 0.0656 (4) 0 (8) 0 (8)
 Spleen 0.267 ± 0.170 (6) 0.168 ± 0.106 (4) 0 (8) 0 (8)
 Submandibular node 0.141 ± 0.0895 (6) 0.528 ± 0.403 (5) 0 (8) 0 (8)
 Mesenteric node 0.0924 ± 0.0914 (5) 1.41 ± 1.12 (4) 0 (8) 0 (8)
Exocrine system
 Parotid gland 0.178 ± 0.113 (6) 0.134 ± 0.0917 (4) 0 (8) 0 (8)
 Submandibular gland 0.305 ± 0.207 (6) 0.168 ± 0.120 (4) 0 (8) 0 (8)
 Sublingual gland 0.169 ± 0.108 (6) 0.105 ± 0.0703 (4) 0 (8) 0 (8)
 Lacrimal gland 0.100 ± 0.0990 (5) 0 (8) 0 (8) 0 (8)
Endocrine system
 Adrenal glands 0.434 ± 0.276 (6) 0.487 ± 0.415 (5) 0 (8) 0 (8)
 Pituitary 0.146 ± 0.101 (6) 0.125 ± 0.0863 (4) 0 (8) 0 (8)
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In summary, we showed, for the first time, that orally 
administered DPAA accumulated in the CNS tissues of 
primates. This finding could contribute to future studies 
to investigate the dynamics and metabolism of DPAA in 
humans.
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